Vaccine Efficacy Estimands Implied by Common Estimators Used in Individual Randomized Field Trials
个体随机实地试验中常用估计量隐含的疫苗效力目标量AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要直接讨论随机试验的因果目标量、排除早期事件后的解释及个体效应敏感性分析,支持因果推断分类。
个体随机实地试验中常用估计量隐含的疫苗效力目标量AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
We review vaccine efficacy (VE) estimands for susceptibility in individual randomized trials with natural (unmeasured) exposure, where individual responses are measured as time from vaccination until an event (e.g., disease from the infectious agent). Common VE estimands are written as $1-θ$, where $θ$ is some ratio effect measure (e.g., ratio of incidence rates, cumulative incidences, hazards, or odds) comparing outcomes under vaccination versus control. Although the ratio effects are approximately equal with low control event rates, we explore the quality of that approximation using a nonparametric formulation. Traditionally, the primary endpoint VE estimands are full immunization (or biological) estimands that represent a subset of the intent-to-treat population, excluding those that have the event before the vaccine has been able to ramp-up to its full effect, requiring care for proper causal interpretation. Besides these primary VE estimands that summarize an effect of the vaccine over the full course of the study, we also consider local VE estimands that measure the effect at particular time points. We discuss interpretational difficulties of local VE estimands (e.g., depletion of susceptibles bias), and using frailty models as sensitivity analyses for the individual-level causal effects over time.